NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it has completed patient enrollment for a clinical trial involving its two human papillomavirus tests.

 

The company said it has enrolled 2,000 normal subjects and 1,400 women with atypical Pap test results. Next steps in the clinical trial include obtaining final colposcopy and biopsy data, validating and opening a database, and submitting pre-market approval applications to the US Food and Drug Administration.